HLA and KIR Region Genomics in Immune-Mediated Diseases (U19 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-19-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding